Oracle Corp. (NASDAQ:ORCL) reported in-line results for Q1, causing Stifel Nicolaus to believe that the results are “healthy,” and the firm believes that Oracle’s outlook remains strong. The firm predicts that the company will beat and raise results during FY13 and has decided to keep its Buy rating.
Don’t Miss: Google Warned to Shape Up.
Sunesis Pharmaceuticals Inc. (NASDAQ:SNSS): According to Cowen, the company’s valuation continues to be attractive due to its ownership of worldwide rights to vosaroxin which which could possibly be a drug worth $500 million or more. Shares have an Outperform rating.
Norfolk Southern Corp. (NYSE:NSC) preannounced that its Q3 EPS did not reach expectations, causing Stifel Nicolaus to think that the stock will recover while the company makes operational changes for the adjustment of lowered demand. The firm keeps a Buy rating but reduced its target to $84 from $93 on the stock.
Oracle Corp. (NASDAQ:ORCL) price target saw an increase of $38 from $34 at Bank of America Merrill Lynch.
Mercadolibre, Inc. (NASDAQ:MELI): According to Stifel Nicolaus, Amazon.com (NASDAQ:AMZN) will enter the Brazil market, and the firm believes that this move will limit appreciation by MercadoLibre’s shares. The firm reiterates its Sell rating on the stock.
Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>